Based on results of large clinical trials, targeted therapy drugs pemigatinib and ivosidenib have been approved by FDA to treat cholangiocarcinoma patients with FGFR2 fusions and IDH1 mutations, respectively [12,13]. This evidence concerns the gene IDH1 and cholangiocarcinoma.